Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes

Darren K. McGuire

University of Texas Southwestern Medical Center, Dallas

Nikolaus Marx

Clinic for Cardiology, Angiology, and Intensive Care Medicine, Rheinisch-Westfälische Technische Hochschule Aachen University, University Hospital Aachen, Aachen, Germany

Sharon L. Mulvagh

Department of Medicine, Division of Cardiology, Dalhousie University, Halifax, NS, Canada

John E. Deanfield

Institute of Cardiovascular Sciences, University College London, London

Silvio E. Inzucchi

Section of Endocrinology, Yale University School of Medicine, New Haven, CT

Rodica Pop-Busui

Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, Portland

Johannes F.E. Mann

Kuratorium für Heimdialyse Kidney Center, Munich, Germany

Scott S. Emerson

Department of Biostatistics, University of Washington, Seattle

Neil R. Poulter

Imperial Clinical Trials Unit, Imperial College London, London

Mads D.M. Engelmann

Novo Nordisk, Søborg, Denmark

Maria Sejersten Ripa

Novo Nordisk, Søborg, Denmark

G. Kees Hovingh

Novo Nordisk, Søborg, Denmark

Kirstine Brown-Frandsen

Novo Nordisk, Søborg, Denmark

Stephen C. Bain

Swansea University Medical School, Swansea, United Kingdom

Matthew A. Cavender

University of North Carolina School of Medicine, Chapel Hill

Mette Gislum

Novo Nordisk, Søborg, Denmark

Jens-Peter David

Novo Nordisk, Søborg, Denmark

John B. Buse